Bind Receives $2M to Advance Platform for Targeted Nanoparticle Engineering
NIST ATP funding will be provided over three years.!--h2>
Bind Biosciences was awarded a three-year $2 million grant to further develop its platform for high-throughput formulation and selection of targeted nanoparticles. The company’s technology has the potential to create a novel class of therapeutics based on optimally engineered targeted polymeric nanoparticles, points out Glenn Batchelder, president and CEO.
The funding was received from the National Institute of Standards and Technology (NIST) under its Advanced Technology Program (ATP). “The ATP funding will accelerate industrialization of our high-throughput combinatorial platform for nanoparticle fabrication and screening that uniquely enables Bind to develop and manufacture targeted nanoparticle therapeutics optimized for a specific disease,” remarks Stephen Zale, Ph.D., vp of development.